Contrary to expectations, when patent regime came to end, many thought this will be the doom for Indian pharma which mainly focussed on reverse engineering. However, Indian pharma companies took the challenge and started investing more right from 2000. Even in recent years, share in R&D over total sales for Wochhardt, Dr. Reddys and Sun Pharma is hovering around 10% while that of MNC’s is a meagre 1%.  Most of the MNC’s now focus to outsource from India rather to invest in R&D here. This trend is emerging very clear as even with less stricter patent laws compared to Europe, more R&D investments were made in Asia compared to Europe.